Endonovo Therapeutics, Inc. (OTCQB: ENDV)

Market Cap: $14.195M, current share price: $.0465


Endonovo's FDA-Cleared and CE Marked non-invasive medical device, SofPulse™, delivers Electroceutical™ therapy to reduce pain and post-surgical swelling. ENDV's SofPulse™ also has CMS National Coverage (Medicare reimbursement) for the treatment of chronic wounds. SofPulse™ aims to reduce the dependency on narcotics following surgeries, such as breast augmentation surgery, by reducing the underlying cause of the pain itself: inflammation. Clinical trials on SofPulse™ have shown a 57% reduction in pain at one hour post breast augmentation surgery, a 300% reduction in pain at 5 hours post surgery, and a 2.2-fold reduction in narcotics use. Furthermore, ENDV is developing its Electroceutical™ therapy for the treatment of cerebrovascular and cardiovascular diseases, which have an underlying inflammatory component. With clinical data showing improvements in SAQ scores for angina severity and physical capacity in patients with end-stage ischemic heart disease and failed medical therapy and revascularization options ("no option" patients), Endonovo Therapeutics, Inc. (ENDV) is severely undervalued compared to its peers, such as Pulse Biosciences and Helius Medical Technologies, and is worth multiples of today's prices.

22nd Century Group, Inc. (NYSE: XXII)

Market Cap: $341.074M, current share price: $2.760

The plant biotechnology company XXII focuses on tobacco harm reduction and hemp/cannabis research. The FDA announced big plans in 2017 to limit nicotine in cigarettes to minimally or non-addictive levels which caused further research published in early 2018 by The National Academies of Sciences, Engineering, and Medicine (NASEM) evaluating the available scientific evidence addressing the short- and long-term health effects related to the use of electronic nicotine delivery systems (ENDS). James E. Swauger, Sr. VP of Sciences and Regulatory Affairs for XXII believes that the Company's Very Low Nicotine tobacco technology demonstrates that the FDA's plan to dramatically reduce nicotine in cigarettes is technologically feasible.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)

Market Cap: $443.799M, current share price: $7.9815

The clinical-stage drug development company, CRBP, targeting rare, chronic, serious inflammatory and fibrotic diseases announced their CEO, Yuval Cohen, Ph.D., will be presenting tomorrow, February 22nd at the 2018 RBC Capital Markets Global Healthcare Conference. Dr. Cohen will present at 3:35pm EST and will be discussing Company's four clinical development programs. A live audio webcast of the fireside chat will be accessible on the Events page of the Investors section of Corbus website and archived on the Company's website for 90 days following the event.

Cardiology Homepage